While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > ORGANIZATION
ORGANIZATION
- MHLW Reports Results of Analysis of “Close-Call” Incidents at Pharmacies with Generics
September 24, 2012
- Mr Hayashi of OPIR Stresses Need for Approval and Reimbursement of More Companion Diagnostics
September 21, 2012
- Dr Fukuda Lays Out 4 Options for HTA Introduction in Drug Pricing
September 20, 2012
- Anti-Japanese Demonstrations in China Have Had “Absolutely No Effect” on Takeda: President Hasegawa
September 20, 2012
- Maker FTC Bans Drink Donations at Academic Conferences
September 19, 2012
- Iyakuhin Renmei to Break Up to Create Unified Pharmaceutical Industry Labor Union
September 14, 2012
- 35% of Domestic Drug Makers Do Not Conduct First-in-Human Trials in Japan: JPMA Survey
September 5, 2012
- Dr Teshirogi of JPMA Comments on Govt’s Efforts to Promote Regulatory Science; Expresses Concerns About Japan’s Future as Drug-Originating Country
September 5, 2012
- Total Number of MRs Up 4.3% at 63,875, Marking Largest Number in History: MR White Paper
September 5, 2012
- JGA Fails to Achieve Goal of Eliminating “Out-of-Stock” Products Yet Again
August 31, 2012
- Generic Market Share at 25.3% in April-June; Marks Largest Increase: JGA
August 28, 2012
- MHLW Must Present Thorough Explanation If It Insists on Lawmaker-Initiated Bill to Establish 3rd-Party Organization: Yakuhiren
August 28, 2012
- AJD Prioritize Brand Unification of Generic Drugs
August 27, 2012
- Wholesaler’s Operating Profit Margin Improves to 0.31%, Yet Far Cry from FY2007 Level: JPWA
August 10, 2012
- PI Forum to Make Proposals to Promote R&D, Make Pharmaceuticals Japan’s Key Industry: Chairman Toyoda
August 9, 2012
- JPMA Calls for Maintenance or Expansion of R&D Tax Credit System at METI Hearings
August 6, 2012
- 61% of Clinics that Issue Legal Prescriptions Claim Premium for Generic-Name Prescribing: JMA Survey
August 3, 2012
- JMA to Draft COI GLs by End of Year
August 3, 2012
- JMA Executive Board Member Komori Calls For Efforts for “Joint Fight” by Municipalities to Slash IPV Price
July 30, 2012
- 4 Pharmaceutical Associations Issue Joint Statement Calling For Eradicating Online Illegal Drug Sales
July 27, 2012
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…